Abstract
The objectives of this study were to assess the clinical effects of an integrated program consisting of concurrent preoperative combined paclitaxel and nedaplatin chemotherapy and three-dimensional conformal radiotherapy followed by surgery intended to cure oral squamous cell carcinoma and to determine whether this integrated program is feasible and effective with respect to the treatment of oral squamous cell carcinoma. A total of 104 biopsy-confirmed patients who presented with oral squamous cell carcinoma for the first time were included in this study. Concurrent preoperative combined paclitaxel and nedaplatin chemotherapy and three-dimensional conformal radiotherapy were administered to these patients. The most common treatment regimen consisted of infusions of paclitaxel (135-175 mg/m(2)/day), infusions of nedaplatin (150 mg; 80-100 mg/m(2)/day), and irradiation at doses ranging from 1.5 Gy twice daily to 30-40 Gy over 3-4 weeks. The clinical variables evaluated herein included the local recurrence rate, distant metastasis rate, postoperative survival rate, and degree of mouth opening restriction. The median follow-up time for surviving patients was 60 months, and the median time to progression for all patients was 57.69 m...Continue Reading
References
Aug 6, 2000·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·F LohrM Wannenmacher
Jan 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lisa LicitraGiulio Cantù
Jan 20, 2005·Journal of the National Cancer Institute·Peyton T Taylor, Doris Haverstick
Mar 14, 2007·Oral Oncology·Kolja FreierChristof Hofele
Jul 4, 2007·Mayo Clinic Proceedings·Deepak Kademani
Oct 26, 2007·The New England Journal of Medicine·Marshall R PosnerUNKNOWN TAX 324 Study Group
Jan 29, 2008·Journal of Cranio-maxillo-facial Surgery : Official Publication of the European Association for Cranio-Maxillo-Facial Surgery·Clemens KlugWerner Millesi
Aug 5, 2008·Oral Oncology·Jatin P Shah, Ziv Gil
Jun 3, 2011·American Journal of Clinical Oncology·Aaron W PedersonDaniel J Haraf
Jul 26, 2011·Periodontology 2000·Richard J ShawChris Butterworth
Oct 24, 2012·Radiation Oncology·Andreas GeretschlägerPirus Ghadjar
Feb 5, 2013·Cancer Chemotherapy and Pharmacology·Hiroyuki HaradaSatoru Shintani
Feb 19, 2013·The Lancet Oncology·Robert HaddadMarshall Posner
Apr 9, 2013·Oral Oncology·Shrinivas RathodJaiprakash Agarwal
Jul 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre BlanchardUNKNOWN Meta-Analysis of Chemotherapy in Head and Neck Cancer, Induction Project, Collaborative Group
Jan 10, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P BossiL Licitra
Sep 16, 2014·Anti-cancer Drugs·Jianping DuYumei Zhang
Oct 15, 2014·Journal of the National Comprehensive Cancer Network : JNCCN·David G PfisterUNKNOWN National Comprehensive Cancer Network
Nov 11, 2014·Current Medical Research and Opinion·L BenjaminC Ricarte
Jan 7, 2015·Gynecologic Oncology·L Andy ChenDavid K Gaffney
Mar 19, 2015·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Zoltán Takácsi-NagyMiklós Kásler
Jun 20, 2015·OncoTargets and Therapy·Francesco PerriPaolo Muto
Jul 1, 2015·Oncotarget·Lai-ping ZhongZhi-yuan Zhang